Symbols / NUVL Stock $104.41 -0.77% Nuvalent, Inc.

Healthcare • Biotechnology • United States • NMS
NUVL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. James R. Porter Ph.D.
Exch · Country NMS · United States
Market Cap 8.25B
Enterprise Value 7.02B
Income -450.07M
Sales —
FCF (ttm) -180.43M
Book/sh 15.96
Cash/sh 16.30
Employees 234
Insider 10d —
IPO Jul 29, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -24.75
PEG —
P/S —
P/B 6.54
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 15.88
Current Ratio 16.14
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -6.06
EPS next Y -4.22
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -22.51%
ROE -41.19%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 73.56M
Shs Float 49.04M
Insider Own 2.76%
Instit Own 112.53%
Short Float 10.77%
Short Ratio 7.99
Short Interest 5.06M
52W High 113.02
vs 52W High -7.61%
52W Low 68.64
vs 52W Low 52.11%
Beta 1.15
Impl. Vol. 53.22%
Rel Volume 0.51
Avg Volume 568.14K
Volume 291.00K
Target (mean) $142.33
Tgt Median $141.00
Tgt Low $116.00
Tgt High $165.00
# Analysts 18
Recom Strong_buy
Prev Close $105.22
Price $104.41
Change -0.77%
About

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$142.33
Mean price target
2. Current target
$104.41
Latest analyst target
3. DCF / Fair value
$-44.15
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$104.41
Low
$116.00
High
$165.00
Mean
$142.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 reit HC Wainwright & Co. Buy → Buy $155
2026-04-08 reit Wedbush Outperform → Outperform $125
2026-03-30 init Wells Fargo — → Overweight $116
2026-02-27 main Cantor Fitzgerald Overweight → Overweight $140
2025-12-19 main JP Morgan Overweight → Overweight $145
2025-11-24 init Truist Securities — → Buy $140
2025-11-18 main Goldman Sachs Buy → Buy $135
2025-11-18 main Baird Outperform → Outperform $158
2025-11-18 main Guggenheim Buy → Buy $155
2025-11-17 main Stifel Buy → Buy $135
2025-11-17 main Leerink Partners Outperform → Outperform $149
2025-11-17 main HC Wainwright & Co. Buy → Buy $155
2025-11-12 init Canaccord Genuity — → Buy $126
2025-10-31 main Barclays Overweight → Overweight $112
2025-10-31 main UBS Buy → Buy $132
2025-10-27 main Piper Sandler Overweight → Overweight $128
2025-10-15 init Cantor Fitzgerald — → Overweight $135
2025-09-08 reit Wedbush Outperform → Outperform $115
2025-09-03 init Raymond James — → Outperform $105
2025-08-19 init Piper Sandler — → Overweight $112
News
RSS: Latest NUVL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-04 PORTER JAMES RICHARD Chief Executive Officer — 30,000 $98.54 $3,050,712
2026-05-04 PORTER JAMES RICHARD Chief Executive Officer — 30,000 $18.93 $567,900
2026-05-01 BALCOM ALEXANDRA Chief Financial Officer — 11,430 $98.42 $1,131,600
2026-05-01 BALCOM ALEXANDRA Chief Financial Officer — 11,430 $1.08 $37,159
2026-04-30 MILLER DEBORAH ANN Officer — 5,500 $99.13 $545,691
2026-04-30 MILLER DEBORAH ANN Officer — 5,500 $6.89 $37,895
2026-04-29 NOCI DARLENE Officer — 5,500 $99.35 $547,524
2026-04-29 NOCI DARLENE Officer — 5,500 $27.85 $153,175
2026-04-09 PELISH HENRY E Officer — 3,093 $104.27 $323,164
2026-04-09 PELISH HENRY E Officer — 3,093 $27.85 $86,140
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
414.31
+47.77%
280.37
+87.55%
149.49
+73.61%
86.11
Research And Development
306.97
+40.96%
217.77
+92.31%
113.24
+77.69%
63.73
Selling General And Administration
107.34
+71.48%
62.59
+72.68%
36.25
+61.99%
22.38
General And Administrative Expense
107.34
+71.48%
62.59
+72.68%
36.25
+61.99%
22.38
Salaries And Wages
63.68
+51.23%
42.11
+82.37%
23.09
+87.46%
12.32
Other Gand A
15.03
+38.50%
10.85
+68.99%
6.42
-71.30%
22.38
Total Expenses
414.31
+47.77%
280.37
+87.55%
149.49
+73.61%
86.11
Operating Income
-414.31
-47.77%
-280.37
-87.55%
-149.49
-73.61%
-86.11
Total Operating Income As Reported
-414.31
-47.77%
-280.37
-87.55%
-149.49
-73.61%
-86.11
EBITDA
-414.31
-47.77%
-280.37
-87.55%
-149.49
-73.61%
-86.11
Normalized EBITDA
-414.31
-47.77%
-280.37
-87.55%
-149.49
-73.61%
-86.11
EBIT
-414.31
-47.77%
-280.37
-87.55%
-149.49
-73.61%
-86.11
Net Income
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Pretax Income
-424.79
-63.39%
-259.99
-105.98%
-126.22
-54.20%
-81.85
Net Non Operating Interest Income Expense
44.73
+16.75%
38.32
+64.64%
23.27
+447.09%
4.25
Net Interest Income
44.73
+16.75%
38.32
+64.64%
23.27
+447.09%
4.25
Interest Income Non Operating
44.73
+16.75%
38.32
+64.64%
23.27
+447.09%
4.25
Interest Income
44.73
+16.75%
38.32
+64.64%
23.27
+447.09%
4.25
Other Income Expense
-55.22
-207.80%
-17.94
—
4.25
Other Non Operating Income Expenses
-55.22
-207.80%
-17.94
—
4.25
Tax Provision
0.58
-23.43%
0.76
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Net Income From Continuing Operation Net Minority Interest
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Net Income From Continuing And Discontinued Operation
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Net Income Continuous Operations
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Normalized Income
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Net Income Common Stockholders
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Diluted EPS
—
-3.93
-81.11%
-2.17
-31.52%
-1.65
Basic EPS
—
-3.93
-81.11%
-2.17
-31.52%
-1.65
Basic Average Shares
—
66.41
+14.06%
58.22
+17.22%
49.67
Diluted Average Shares
—
66.41
+14.06%
58.22
+17.22%
49.67
Diluted NI Availto Com Stockholders
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Insurance And Claims
28.63
+197.14%
9.63
+42.98%
6.74
+23.36%
5.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,412.70
+23.73%
1,141.75
+55.90%
732.38
+51.80%
482.46
Current Assets
1,392.43
+22.96%
1,132.45
+55.88%
726.49
+51.99%
477.99
Cash Cash Equivalents And Short Term Investments
1,371.95
+22.68%
1,118.30
+55.34%
719.90
+52.47%
472.16
Cash And Cash Equivalents
261.75
+79.66%
145.69
-56.56%
335.39
+38.70%
241.81
Other Short Term Investments
1,110.21
+14.15%
972.61
+152.94%
384.52
+66.92%
230.36
Prepaid Assets
—
—
—
—
Other Current Assets
20.47
+44.73%
14.15
+114.89%
6.58
+12.95%
5.83
Total Non Current Assets
20.28
+117.96%
9.30
+57.80%
5.90
+31.96%
4.47
Other Non Current Assets
20.28
+117.96%
9.30
+57.80%
5.90
+31.96%
4.47
Total Liabilities Net Minority Interest
164.37
+128.41%
71.96
+126.13%
31.82
+63.35%
19.48
Current Liabilities
91.17
+68.77%
54.02
+69.75%
31.82
+63.35%
19.48
Payables And Accrued Expenses
74.24
+70.39%
43.57
+77.85%
24.50
+67.46%
14.63
Payables
30.16
+477.19%
5.22
-43.66%
9.27
+28.90%
7.20
Accounts Payable
30.16
+477.19%
5.22
-43.66%
9.27
+28.90%
7.20
Current Accrued Expenses
44.08
+14.96%
38.34
+151.88%
15.22
+104.78%
7.43
Pensionand Other Post Retirement Benefit Plans Current
16.93
+62.03%
10.45
+42.67%
7.33
+50.99%
4.85
Total Non Current Liabilities Net Minority Interest
73.19
+308.00%
17.94
0.00
0.00
Tradeand Other Payables Non Current
0.00
0.00
0.00
—
Other Non Current Liabilities
0.04
—
—
—
Stockholders Equity
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Common Stock Equity
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Capital Stock
0.01
+0.00%
0.01
+14.29%
0.01
+16.67%
0.01
Common Stock
0.01
+0.00%
0.01
+14.29%
0.01
+16.67%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
78.24
+9.66%
71.34
+11.36%
64.07
+13.05%
56.67
Ordinary Shares Number
78.24
+9.66%
71.34
+11.36%
64.07
+13.05%
56.67
Additional Paid In Capital
2,218.41
+37.20%
1,616.89
+63.85%
986.82
+58.26%
623.54
Retained Earnings
-972.43
-77.76%
-547.05
-91.08%
-286.30
-78.85%
-160.08
Gains Losses Not Affecting Retained Earnings
2.35
+4088.14%
-0.06
-290.32%
0.03
+106.28%
-0.49
Other Equity Adjustments
2.35
+4088.14%
-0.06
-290.32%
0.03
+106.28%
-0.49
Total Equity Gross Minority Interest
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Total Capitalization
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Working Capital
1,301.26
+20.66%
1,078.43
+55.24%
694.66
+51.50%
458.51
Invested Capital
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Net Tangible Assets
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Tangible Book Value
1,248.34
+16.69%
1,069.79
+52.71%
700.56
+51.32%
462.98
Dueto Related Parties Non Current
73.16
+307.80%
17.94
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-275.21
-48.71%
-185.06
-85.55%
-99.74
-53.51%
-64.97
Cash Flow From Continuing Operating Activities
-275.21
-48.71%
-185.06
-85.55%
-99.74
-53.51%
-64.97
Net Income From Continuing Operations
-425.38
-63.13%
-260.76
-106.59%
-126.22
-54.20%
-81.85
Other Non Cash Items
44.46
+1259.16%
3.27
+132.36%
-10.11
-2610.19%
-0.37
Stock Based Compensation
86.50
+42.79%
60.58
+136.98%
25.56
+147.58%
10.32
Change In Working Capital
19.21
+62.20%
11.84
+7.40%
11.03
+59.08%
6.93
Change In Prepaid Assets
-6.34
+16.14%
-7.56
-1274.38%
0.64
+143.19%
-1.49
Change In Payables And Accrued Expense
36.06
+58.06%
22.81
+93.17%
11.81
+21.83%
9.69
Change In Accrued Expense
11.46
-57.34%
26.86
+178.62%
9.64
+75.87%
5.48
Change In Payable
24.60
+707.53%
-4.05
-286.68%
2.17
-48.50%
4.21
Change In Account Payable
24.60
+707.53%
-4.05
-286.68%
2.17
-48.50%
4.21
Change In Other Current Assets
-10.51
-208.33%
-3.41
-138.66%
-1.43
-12.26%
-1.27
Investing Cash Flow
-124.08
+78.37%
-573.51
-299.59%
-143.53
-1245.78%
-10.66
Cash Flow From Continuing Investing Activities
-124.08
+78.37%
-573.51
-299.59%
-143.53
-1245.78%
-10.66
Net Investment Purchase And Sale
-124.08
+78.37%
-573.51
-299.59%
-143.53
-1245.78%
-10.66
Purchase Of Investment
-1,057.77
-3.20%
-1,024.96
-123.07%
-459.49
-115.81%
-212.92
Sale Of Investment
933.69
+106.82%
451.45
+42.88%
315.96
+56.22%
202.25
Financing Cash Flow
515.34
-9.41%
568.88
+68.88%
336.85
+35.33%
248.92
Cash Flow From Continuing Financing Activities
515.34
-9.41%
568.88
+68.88%
336.85
+35.33%
248.92
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
515.72
-9.52%
569.99
+68.40%
338.48
+35.14%
250.47
Proceeds From Stock Option Exercised
—
—
14.18
+670.65%
1.84
Net Other Financing Charges
-0.38
+65.43%
-1.10
+32.33%
-1.63
-5.08%
-1.55
Changes In Cash
116.05
+161.18%
-189.70
-302.71%
93.58
-45.99%
173.28
Beginning Cash Position
145.69
-56.56%
335.39
+38.70%
241.81
+252.87%
68.53
End Cash Position
261.75
+79.66%
145.69
-56.56%
335.39
+38.70%
241.81
Free Cash Flow
-275.21
-48.71%
-185.06
-85.55%
-99.74
-53.51%
-64.97
Amortization Of Securities
—
—
-10.11
-2610.19%
-0.37
Common Stock Issuance
515.72
-9.52%
569.99
+68.40%
338.48
+35.14%
250.47
Issuance Of Capital Stock
515.72
-9.52%
569.99
+68.40%
338.48
+35.14%
250.47
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category